Search research articles
Contact Us
Filters
Showing results (81-90 of 173) with videos related to
Page
of 18
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2010
Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Bioconjugate Chemistry
|
April 18, 2018
Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin
Emmanouil Lymperis, Aikaterini Kaloudi, Werner Sallegger, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 12, 2008
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
Martijn van Essen, Eric P Krenning, Boen L Kam, et al.
Pharmaceutics
|
March 26, 2022
Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK<sub>2</sub>R Cancer Theranostic Agents: A Preclinical Study
Berthold A Nock, Panagiotis Kanellopoulos, Oleg G Chepurny, et al.
International Journal of Molecular Sciences
|
February 10, 2024
Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [<sup>111</sup>In]In-Radioligands: Synthesis and Preclinical Profile
Aikaterini Tatsi, Theodosia Maina, Beatrice Waser, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 30, 2007
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
Martijn van Essen, Eric P Krenning, Willem H Bakker, et al.
Neuroendocrinology
|
January 13, 2012
Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy
Esther I van Vliet, Jaap J M Teunissen, Boen L R Kam, et al.
Nuclear Medicine and Biology
|
July 13, 2004
Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+
Wouter A P Breeman, Maarten Th M De Jong, Erik De Blois, et al.
Cancer Research
|
November 15, 2012
mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer
Stefan E Pool, Sander Bison, Stuart J Koelewijn, et al.
EJNMMI Research
|
June 12, 2012
[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study
Aikaterini Tatsi, Theodosia Maina, Renzo Cescato, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 173) with videos related to
Sort By:
Page
of 18
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2010
Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Bioconjugate Chemistry
|
April 18, 2018
Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin
Emmanouil Lymperis, Aikaterini Kaloudi, Werner Sallegger, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 12, 2008
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
Martijn van Essen, Eric P Krenning, Boen L Kam, et al.
Pharmaceutics
|
March 26, 2022
Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK<sub>2</sub>R Cancer Theranostic Agents: A Preclinical Study
Berthold A Nock, Panagiotis Kanellopoulos, Oleg G Chepurny, et al.
International Journal of Molecular Sciences
|
February 10, 2024
Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [<sup>111</sup>In]In-Radioligands: Synthesis and Preclinical Profile
Aikaterini Tatsi, Theodosia Maina, Beatrice Waser, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 30, 2007
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
Martijn van Essen, Eric P Krenning, Willem H Bakker, et al.
Neuroendocrinology
|
January 13, 2012
Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy
Esther I van Vliet, Jaap J M Teunissen, Boen L R Kam, et al.
Nuclear Medicine and Biology
|
July 13, 2004
Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+
Wouter A P Breeman, Maarten Th M De Jong, Erik De Blois, et al.
Cancer Research
|
November 15, 2012
mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer
Stefan E Pool, Sander Bison, Stuart J Koelewijn, et al.
EJNMMI Research
|
June 12, 2012
[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study
Aikaterini Tatsi, Theodosia Maina, Renzo Cescato, et al.
Page
of 18